(News Bulletin 247) – Pfizer announced yesterday evening positive results from a phase 3 program evaluating the efficacy, safety and tolerability of the new experimental antibiotic combination aztreonam-avibactam (ATM-AVI) in the treatment of serious bacterial infections due to Gram-negative bacteria, including multidrug-resistant pathogens for which there are few or no treatment options.
The data confirms that ATM-AVI is effective and well tolerated, with no new safety findings and with a similar safety profile to aztreonam alone.
“We believe these data demonstrate that ATM-AVI, if approved, could be an important treatment option for patients with life-threatening bacterial infections that are resistant to nearly all currently available antibiotics,” said said James Rusnak, senior vice president and chief development officer at Pfizer.
“We are committed to meeting this critical need and helping to address the global health threat posed by antimicrobial resistance,” he added.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
